Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers is a research paper published in Vaccines (2021). On theSindex it has a DataRank of 0. It has been cited 33 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 1R01CA238273-01A1; 1R01CA242917-01A1
National Institutes of Health
Grant: 1R01CA238273-01A1
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer
National Institutes of Health
Grant: 1R01CA242917-01A1
Identifying a New Biological Target for Breast Cancer Therapy That Contributes to Disparities for African-American Women
FWCI
1.61
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals
Additional file 1 of Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer
Additional file 1 of Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer